LL-37

Speaker cites a 2022 study by Prusty in Viruses examining comprehensive HSV management combining immune training peptides, antiviral compounds, nerve repair peptides, and nutrient restoration. Results showed 76% reduction in outbreak frequency, 89% reduction in outbreak severity, 84% reduction in neuropathic pain, with sustained improvement at 12-month follow-up.

LL-37 administered IM daily acts as an antimicrobial peptide that directly kills HSV by disrupting the viral envelope and enhances interferon production by 43%. Speaker cites a 2016 study by Chrom in PenAs showing LL-37 reduced HSV reactivation frequency by 52%.

Speaker specifically chose intramuscular (IM) administration for Thymosin Alpha-1, LL-37, and BPC-157 rather than subcutaneous, stating the rationale was faster absorption needed in active viral suppression cases. KPV was the exception, administered subcutaneously.

Complete protocol combining immune retraining (Thymosin Alpha-1 IM 2x/week, LL-37 IM daily), direct antivirals (Monolaurin 3g/day, L-Lysine 3g/day in 3 divided doses), anti-inflammatory control (KPV 300-400mcg subQ daily), nerve repair (BPC-157 IM daily), and nutritional restoration (Magnesium glycinate 400mg, Zinc 30mg, Vitamin D3 5000IU + K2 200mcg, Selenium 200mcg, NAC 600mg 2x/day). Patient achieved zero outbreaks in 90 days after 8 years of monthly outbreaks.